DV
Dividend Vision

SPRY — ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. (SPRY)

Total return is -77.4% over the past 5.7 years, 204.4 points behind SPY at 127.0%. Its deepest 1-year drawdown was 67.6%.

SPRY is a single-stock equity holding in ARS Pharmaceuticals, a healthcare company, rather than a diversified ETF fund. The holding does not currently distribute dividends, making it unsuitable for income-focused strategies. This concentrated position appeals primarily to growth-oriented investors seeking exposure to the pharmaceutical sector's potential capital appreciation.

SPRY key facts

Asset type
Stock
Asset class
Equity
Inception date
12/04/2020
Distribution frequency
None
Last close
$5.65
Market cap
$561,063,424
Average volume
5046019.0
Beta
0.972
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.00